Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678935 | 0.83 | KMT2A (0.57) | KMT2AMEN1NPC1L3MBTL1 | |
| SCHEMBL4390848 | 0.80 | CHRM3 (0.48) | SIGMAR1KMT2AMEN1CACNA2D1CACNA1B | |
| SCHEMBL4388744 | 0.79 | ALDH1A1 (0.60) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL5027817 | 0.79 | CACNA2D1 (0.63) | OPRD1KMT2AMEN1CACNA2D1CACNA1B | |
| SCHEMBL29092017 | 0.75 | SIGMAR1 (0.46) | SIGMAR1OPRD1NPC1 | |
| SCHEMBL3011662 | 0.75 | NPC1 (0.77) | KMT2AMEN1NPC1L3MBTL1 | |
| SCHEMBL1189519 | 0.75 | ALDH1A1 (0.63) | SIGMAR1KMT2AMEN1SLC6A4 | |
| SCHEMBL1677888 | 0.75 | TSHR (0.56) | SIGMAR1OPRD1KMT2AMEN1 | |
| SCHEMBL24672685 | 0.73 | ALDH1A1 (0.61) | SIGMAR1KMT2AMEN1SLC6A4 | |
| Hydrochloric Acid SCHEMBL1763146 | 0.73 | ALDH1A1 (0.61) | SIGMAR1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SIGMAR1 407/4885OPRD1 190/4885KMT2A 1220/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SIGMAR1 407/4885OPRD1 190/4885KMT2A 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.